Mode
Text Size
Log in / Sign up
N/A Completed N=509

Prospective, Open-label Tolerability and Safety Monitoring Study of Novantrone in a Selected Cohort of Multiple Sclerosis Patients

Source: ClinicalTrials.gov NCT00262314 ↗
Enrolled (actual)
509
Serious AEs
20.0%
Results posted
Jun 2010
Primary outcomePrimary: Congestive Heart Failure (Treatment Phase) — 6 participants

Summary

The overall objective of this study is to collect data relevant to the tolerability of Novantrone® therapy in patients with multiple sclerosis (MS) using dosing and monitoring recommendations specified in the package insert.

Outcome Measures

OutcomeResultp-value
PRIMARY
Congestive Heart Failure (Treatment Phase)
6 —
PRIMARY
Congestive Heart Failure (Annual Follow-Up Phase)
4 —
PRIMARY
Left Ventricular Ejection Fraction (Treatment Phase)
27 —
PRIMARY
Left Ventricular Ejection Fraction (Annual Follow-Up Phase)
14 —
PRIMARY
Serious Infections (Treatment Phase)
50 —
PRIMARY
Serious Infections (Annual Follow-Up Phase)
— —
PRIMARY
IV Antibiotics (Individual Drugs Unspecified) Utilized Due to Serious Infection (Treatment Phase)
40 —
PRIMARY
IV Antibiotics (Individual Drugs Unspecified) Utilized Due To Serious Infection (Annual Follow-Up Phase)
— —
PRIMARY
Severe Neutropenia (Treatment Phase)
9 —
PRIMARY
Severe Neutropenia (Annual Follow-Up Phase)
— —
PRIMARY
Clinical Relapses (Treatment Phase)
185 —
PRIMARY
Clinical Relapses (Annual Follow-Up Phase)
60 —
PRIMARY
Symptomatic CHF, Left Ventricular Ejection Fraction - Prior to Each Dose • Serious Infections, IV Antibiotics, or Assoc w/ Severe Neutropenia-evaluated. Novantrone Admin - Per PI • SAE, Clinical Relapses
— —

Eligibility Criteria

Inclusion Criteria

  • To be eligible for inclusion into this study, the subjects must fulfill all of the following criteria:
  • Platelet count >100,000 cells/µL
  • Granulocyte count > 2000 cells/µL
  • Age 18-65 years
  • Negative pregnancy test for female patients who are biologically capable of becoming pregnant, even if they are taking birth control
  • For patients of reproductive age, agreement to practice effective contraception throughout the study and for 6 months following the last administration of Novantrone®
  • Signed Inform Consent.

Exclusion Criteria

  • To be eligible for inclusion in this study the subjects must not meet any of the following criteria:
  • Presence of cardiac risk factors:
  • History of congestive heart failure
  • LVEF 2x upper limits of normal
  • Severe untreated infection (including current urinary tract infection)
  • Nursing or pregnant women)
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00262314). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search